Subscribe
Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

JAMA Editor’s Summary

Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the
June 26, 2018

Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

Editor’s Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the June 26, 2018 issue

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

cover
Cultivating Resilience During Times of Crisis and Existential Threat Keith interviews Dr. Chris Recinos, the CEO and founder of Nurse Leader Network, regarding mental health, adaptive and maladaptive mechanisms of resilience, and conscious self-development.